Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC008 in CLDN18.2-positive advanced solid tumors
NCT05837299Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMC008 in gastric cancer (GC), esophagogastric junction adenocarcinoma (GEJA) and pancreatic cancer (PC), sponsored by Changhai Hospital. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
IMC008
03
Conditions
gastric cancer (GC)esophagogastric junction adenocarcinoma (GEJA)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05837299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837299.